Introduction
It is well known that inflammation and oxidative stress play a crucial role in the pathogenesis of all phases of atherosclerosis [1, 2] . Among the subtypes of leucocytes, monocytes are especially important in the pathogenesis of atherosclerosis due to their secretion capability of pro-inflammatory and pro-oxidant cytokines [3] . In contrast, high density lipoprotein cholesterol (HDL-C) was shown to have anti-inflammatory, anti-oxidant, and anti-thrombotic effects [4, 5] . Association of high monocyte count and low HDL-C with inflammation and oxidative stress led physicians to testing a new marker called monocyte to high-density lipoprotein cholesterol ratio (MHR) in cardiovascular conditions. First, Kanbay et al. [6] found that increased MHR is associated with major cardiovascular events in chronic kidney disease. Subsequent studies revealed the association of MHR with atrial fibrillation recurrence after cryoballoon-based catheter ablation, coronary slow flow, coronary artery ectasia and stent thrombosis after ST-segment elevation myocardial infarction (STEMI) [7] [8] [9] [10] .
Recently, Karataş et al. [11] demonstrated that MHR values were independently associated with in-hospital mortality in patients with STEMI. However, value of the MHR in prediction of long-term prognosis of STEMI patients has not been studied so far. Therefore, the aim of the present study was to investigate the relationship of MHR with in-hospital and 5-year major adverse cardiac events (MACE) and mortality of STEMI patients managed with primary percutaneous coronary intervention (PCI).
Methods

Study population
One thousand, five hundred and ninety-eight consecutive patients with STEMI, who were admitted to the Emergency Department and underwent urgent cardiac catheterization between December 2009 and December 2013, were enrolled into the study. Patients with acute infection, hematological diseases, malignancy, and chronic systemic disease were excluded from the study. The patients were divided into tertiles according to their MHR levels. STEMI was defined as ischemia symptoms and ≥ 1 mm ST-segment elevation of in at least 2 contiguous electrocardiogram (ECG) leads except V2-V3 which required 1.5 mm for female patients, 2 mm for male patients > 40 years old, and 2.5 mm for male patients < 40 years old or new onset left bundle-branch block. The study protocol was approved by the Institutional Ethics Committee.
Analysis of patient data
The demographic information, medical history, and cardiovascular risk factors of the patients were obtained from their medical records. On admission, blood values were obtained from all patients. A 12--lead ECG was recorded in each patient just after hospital admission, and the myocardial infarction type was also obtained from the ECGs. From 24 h to 72 h after revascularization, a transthoracic echocardiography was performed by using a system V (Vingmed, GE, Horten, Norway) with a 2.5-MHz phased-array transducer, and the left ventricular ejection fraction (LVEF) was calculated using a modified Simpson's method.
Coronary angiography and PCI
All patients were given a chewable 300 mg aspirin and 600 mg loading dose of clopidogrel before coronary angiography. After the procedure, all patients were prescribed 100 mg aspirin and 75 mg clopidogrel daily. Angiographic data of the patients were assessed from catheter laboratory records. All procedures were performed via femoral route. Angiographic evaluation was made by visual assessment. Primary angioplasty (including balloon angioplasty and/or stent implantation) was performed just for infarct-related artery according to lesion type. For each procedure, interventional success at the acute phase was defined as reducing to < 30% of obstruction and stenosis of the infarct-related artery with Thrombolysis in Myocardial Infarction (TIMI) 3 flow just after primary angioplasty. The use of tirofiban was left to the discretion of the operator.
Laboratory analysis
Basic hematologic parameters, such as monocyte count were determined by a Coulter LH Series hematology analyzer (Beckman Coulter, Inc, Hialeah, Florida). Serum total cholesterol, triglyceride, and HDL-L concentrations were analyzed by a BMHitachi-747 auto analyzer (Boehringer Mannheim GmbH, Mannheim, Germany). Serum low-density lipoprotein cholesterol (LDL-L) values were estimated by the formula of Friedewald or directly measured if triglyceride > 400 mg/dL.
Definitions
Patients were assessed according to Killip classification [14] . Non-diabetic patients were defined as patients without documented diabetes using neither oral hypoglycemic agents nor insulin treatment at admission. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg or current antihypertensive medicine use; a family history of coronary artery disease was defined as documented case of coronary artery disease in a parent or sibling before 60 years of age; smoking was defined as current tobacco use; in-hospital mortality was defined as mortality due to any cause during hospital stay, and long-term mortality was defined as mortality due to any cause during 60 month follow up; in-hospital MACE was defined as reinfarction, stroke, target vessel revascularization, ventricular arrhythmia, cardiopulmonary resuscitation and death during index hospitalization; long term MACE was defined as death, stroke, reinfarction and target vessel revascularization during 60-month follow-up.
Statistical analysis
Analyses were performed using SPSS Statistics version18.0 for Windows (SPSS Inc, Chicago, IL). The Kolmogorov-Smirnov method was used to test the distribution pattern. Data were presented as mean and standard deviation, median and in-terquartile range, or proportions. The one way ANOVA was used to compare data with normal distribution and Kruskal-Wallis test was applied to compare the data without normal distribution. Categorical variables were compared with the c 2 test. The effects of different variables on clinical outcomes were assessed by Cox regression analysis. The variables for which the unadjusted p value was < 0.10 in univariate Cox regression analysis were identified as potential risk markers and included in the multivariable Cox regression model. Monocyte to HDL ratio was used as a continuous variable rather than tertiles in Cox regression models. The survival curves during hospitalization and follow-up for MHR were analyzed using the Kaplan-Meier method, and statistical assessment was performed using the log-rank test. A p value < 0.05 was considered statistically significant for all analyses.
Results
Baseline characteristics of the study population are summarized in Table 1 . Mean age of the participants was 56.1 ± 11.8 years and mean follow-up duration was 23.4 ± 15.8 months. Twenty--three (1.4%) patients died during hospital stay and 132 (8.7%) patients died during the follow-up. In multivariate Cox regression analysis, age (HR = = 1.144, 95% CI 1.067-1.227, p = 0.001), HDL (HR = 0.894, 95% CI 0.819-0.977, p = 0.013), white blood cell (WBC) count (HR = 1.258, 95% CI 1.010-1.459), and MHR (HR = 3.745, 95% CI 1.308-5.950) were found as independent predictors of in-hospital mortality (Table 2 ). Monocyte to HDL ratio was also found as an independent predictor of long-term mortality (HR = 2.048, 95% CI 1.225-4.091, p = 0.014) along with diabetes mellitus (HR = 2.279, 95% CI 1.197-4.340, p = = 0.012), LVEF (HR = 0.958, 95% CI 0.938-0.978, p < 0.001), and hemoglobin (HR = 0.795, 95% CI 0.679-0.930, p = 0.004) (Table 3) , while WBC count (HR = 1.073, 95% CI 1.000-1.152, p = 0.049) and MHR (HR 1.501, 95% CI 1.015-1.993, p = 0.022) were found as independent predictors of in-hospital MACE (Table 4 ). In addition, LVEF (HR 0.980, 95% CI 0.967-0.993, p = 0.003), hemoglobin (HR 0.909, 95% CI 0.829-0.996, p = 0.041), and MHR (HR 1.285, 95% CI 1.064-1.552, p = 0.009) were found as independent predictors of long-term MACE (Table 5 ). Kaplan-Meier curves among tertiles for both in-hospital and 5-year MACE and mortality, which represent worse outcomes as MHR increases, were shown in Figure 1 .
Discussion
The main finding of the present study was that MHR level is independently associated with both in-hospital and 5-year MACE, and mortality of STEMI patients. As far as we know, this is the first study to report relationship of MHR with long-term prognosis in STEMI. In addition, findings of this study confirm a previous study with smaller patient count [11] revealing the association of in-hospital mortality and MACE with MHR in STEMI.
Monocytes are essential immune system cells with unique roles during inflammatory response and contribute the pathophysiology of all stages of atherosclerosis. In the presence of endothelial dysfunction, monocytes attach to endothelium and migrate to sub-endothelial space where they mature into macrophages which then differentiate into the foam cells by taking up oxidized LDL via scavenger receptors SR-A and CD-36 [12] . Next, foam cells secrete pro-inflammatory cytokines, matrix metalloproteinases, growth factors and tissue factor [13] . As a result, smooth muscle proliferation occurs and results in plaque growth. Furthermore, matrix metalloproteinases inflict damage to elastic lamina and predispose to plaque rupture. If the plaque rupture occurs, tissue factor acts as a co-factor for factor VII and causes thrombin production resulting in thrombus formation and acute coronary syndromes [14] . Impact of the monocytes on atherosclerosis seems to be correlated with circulating monocyte count which was found to be predictive of new plaque development [15, 16] .
As the so-called good cholesterol, HDL-C protects endothelial cells from inflammation and oxidative stress by several mechanisms. First, HDL-C prevents monocyte recruitment into the artery wall by inhibiting the expression of endothelial adhesion molecules [17] . In addition, HDL-C has a role in control of the monocyte activation and proliferation of monocyte progenitor cells [18] [19] [20] . Furthermore, HDL-C inhibits oxidation of LDL-C and promotes efflux of oxidized LDL-C from foam cells [5, 18] .
Association of HDL-C and inflammation is not just about the anti-inflammatory action of HDL-C. During inflammation, there is a reduction in levels of HDL-C and some plasma proteins are involved in HDL-mediated reverse cholesterol transport and inhibiting plasma lipid oxidation, such as apolipoprotein A-I and paraoxonase [21] . In addition, HDL-C loses cholesterol ester but gains free cholesterol, triglyceride, and free fatty acids [22] . The levels www.cardiologyjournal.org of apolipoprotein J and serum amyloid-A increase several fold in this "acute-phase HDL" [23] . Acute phase HDL behaves differently from normal HDL and was shown to be less effective in removing cholesterol from macrophages [24] . Thereforeo, HDL-C is a negative acute phase reactant and lower HDL-C levels may reflect more inflammation, as well as less anti-inflammatory activity.
Value of the MHR has been revealed in several cardiovascular conditions so far [6] [7] [8] [9] [10] [11] . In addition, our study showed that MHR was found to be an independent predictor of long-term prognosis of STEMI patients, while such an association was not present for monocyte or HDL-C alone. Thus, as a combination of two parameters related with inflammation and oxidative stress, MHR may have potential to be a valuable prognosis marker in cardiology and deserve to be investigated in other cardiovascular conditions.
Limitations of the study
The present study has some limitations. First, it is a retrospective and single center study. In addition, a single MHR value was used for analysis rather than a temporal trend. Another limitation of the study is that other inflammation and oxidative stress markers, such as C-reactive protein, were not used. In addition, the use of newer drugs such as prasugrel and ticagrelor instead of clopidogrel may alter the results of the study.
Conclusions
In conclusion, results of the present study showed that MHR is an independent predictor of in-hospital and 5-year MACE and mortality in STEMI patients. Prospective studies are needed to confirm our findings and elucidate the value of MHR in prediction of prognosis after STEMI.
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